H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, describes progression free survival (PFS) for patients with advanced nonsquamous non–small cell lung cancer (NSCLC) in the PARAMOUNT phase III trial examining continuation maintenance therapy in two randomized arms; one receiving pemetrexed in addition to best supportive care and the other placebo and best supportive care.